Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
SL-01
Cat No.
CEI-0887
Description
SL-01 is a p53-Mdm2 interaction inhibitor with IC50 of 3.18 μM.
CAS No.
26049-94-5
Molecular Weight
331.79
Storage
2 years -20 centigrade Powder; 2 weeks 4 centigrade in DMSO; 6 months -80 centigrade in DMSO.
Targets
p53, Mdm2
IC50
3.18 μM
Molecular Formula
C18H18ClNO3
Chemical Name
Carbamic acid, N-[(1S)-3-chloro-2-oxo-1-(phenylmethyl)propyl]-, phenylmethyl ester
Solubility
DMSO 50 mg/mL heat ; Water mg/mL; Ethanol 15 mg/mL heat
In vitro
SL-01 inhibits the proliferation of lung carcinoma cell lines NCI-H460 and A549, hepatocellular carcinoma cell lines Bel7402 and HepG2, and colon adenocarcinoma cell line HCT-116 with IC50s of 20, 20, 8, 6 and 20 μM, respectively, which are higher than that of gemcitabine. SL-01 induces the cancer cells to apoptosis showing chromatin condensation and externalization of phosphatidylserine. In concentrations of SL-01 from 2 to 8 μM, the percentages of apoptotic cells are increased from 16.8% to 39.6%, for NCI-H460 cells.
In vivo
SL-01 effectively inhibits human hepatocellular carcinoma HepG2 xenograft growth after 20 days of oral administration (Table 6 and Figure 2A). The rates of inhibition by 21.5, 17.2 and 12.9 μmol⁄kg of SL-01 once per day are 58.0%, 42.1% and 31.8%, respectively. In human colon adenocarcinoma HCT-116 xenografts, the rates of inhibition by SL-01 are 69.3%, 47.8% and 39.1% after 16 days of oral administration at 25.8, 21.5 and 17.2 μmol⁄kg, respectively. SL-01 is well tolerated by mice with no significant loss in body mass or other apparent signs of toxicity. The SL-01 induces NCI-H460 cells apoptosis in vivo. After 3 weeks treatment, the percentages of TUNEL staining positive cells in NCI-H460 xenografts treated by 10, 20 and 30 μmol/kg of SL-01 are 25.6%, 41.7% and 54.3%, respectively. SL-01 significantly increases the expression of cleaved caspase-9 and cleaved caspase-3. The percentages of increase in cleaved PARP by 10, 20, 30 μmol/kg of SL-01 are 42.3%, 109.3% and 133.2%, respectively. SL-01-treated cancer tissues exhibits the activation of Bax/Bcl-2 ratio.
Download
Download Datasheet